适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hodgkin´s lymphoma (histologically proven)
- •CS(PS) IIB with one or both of the risk factors:
- •bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
- •extranodal involvement
- •CS(PS) III, IV
- •written informaed consent
排除标准
- •Leukocytes <3000/microl
- •Platelets <100000/microl
- •Hodgkin´s Disease as "composite lymphoma"
- •Activity index (WHO) < grade 2
研究者
相似试验
已完成
3 期
HD11 for Intermediate StagesHodgkin´s LymphomaNCT00264953University of Cologne1,395
进行中（未招募）
3 期
HD21 for Advanced StagesClassical Hodgkin LymphomaNCT02661503University of Cologne1,500
招募中
不适用
Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three FractionsVentricular TachycardiaNCT06743789Weill Medical College of Cornell University40
已完成
3 期
HD10 for Early StagesHodgkin´s LymphomaNCT00265018University of Cologne1,370
终止
1 期
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaLymphoma, Non-HodgkinNCT02954406Millennium Pharmaceuticals, Inc.43